Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2022 | 407 | 3.670 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2024 | 61 | 1.610 |
Why?
|
| Hematologic Diseases | 3 | 2017 | 78 | 1.090 |
Why?
|
| Immunotherapy | 2 | 2020 | 724 | 0.900 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 922 | 0.900 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2024 | 215 | 0.770 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 49 | 0.750 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 90 | 0.710 |
Why?
|
| Ploidies | 1 | 2019 | 41 | 0.620 |
Why?
|
| Child | 17 | 2024 | 7323 | 0.610 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 65 | 0.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 2556 | 0.510 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 268 | 0.490 |
Why?
|
| Immune System Diseases | 1 | 2015 | 27 | 0.480 |
Why?
|
| Adolescent | 18 | 2022 | 9493 | 0.470 |
Why?
|
| Burkitt Lymphoma | 1 | 2014 | 33 | 0.440 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 102 | 0.420 |
Why?
|
| Oxides | 2 | 2010 | 43 | 0.420 |
Why?
|
| Arsenicals | 2 | 2010 | 48 | 0.410 |
Why?
|
| Young Adult | 16 | 2021 | 6615 | 0.400 |
Why?
|
| Child, Preschool | 9 | 2024 | 3812 | 0.360 |
Why?
|
| Folic Acid | 1 | 2011 | 64 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1397 | 0.350 |
Why?
|
| Carnitine | 2 | 2021 | 14 | 0.330 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2010 | 41 | 0.330 |
Why?
|
| Asparaginase | 2 | 2021 | 35 | 0.330 |
Why?
|
| Humans | 34 | 2024 | 92175 | 0.330 |
Why?
|
| Infant | 6 | 2024 | 3211 | 0.320 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2021 | 66 | 0.320 |
Why?
|
| Communicable Diseases | 1 | 2010 | 65 | 0.310 |
Why?
|
| Injections, Spinal | 2 | 2022 | 47 | 0.310 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 204 | 0.310 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 2368 | 0.310 |
Why?
|
| Glucocorticoids | 1 | 2010 | 366 | 0.280 |
Why?
|
| Polyethylene Glycols | 2 | 2021 | 361 | 0.280 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1575 | 0.280 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 827 | 0.280 |
Why?
|
| Neoplasms | 3 | 2020 | 3114 | 0.270 |
Why?
|
| Remission Induction | 5 | 2019 | 763 | 0.260 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 31 | 0.230 |
Why?
|
| Male | 19 | 2024 | 43858 | 0.220 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 262 | 0.220 |
Why?
|
| Female | 19 | 2024 | 47822 | 0.210 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 1179 | 0.210 |
Why?
|
| Prognosis | 4 | 2020 | 3861 | 0.200 |
Why?
|
| Leukemia, B-Cell | 1 | 2022 | 23 | 0.190 |
Why?
|
| Etoposide | 2 | 2019 | 206 | 0.190 |
Why?
|
| Methotrexate | 1 | 2022 | 245 | 0.180 |
Why?
|
| Survivors | 2 | 2020 | 199 | 0.180 |
Why?
|
| Cytogenetic Analysis | 2 | 2019 | 71 | 0.180 |
Why?
|
| Retrospective Studies | 5 | 2022 | 9675 | 0.170 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 188 | 0.160 |
Why?
|
| Anthracyclines | 1 | 2019 | 35 | 0.160 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 355 | 0.160 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2513 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2024 | 8725 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 814 | 0.160 |
Why?
|
| Postoperative Complications | 1 | 2010 | 2451 | 0.150 |
Why?
|
| Leukemia | 1 | 2021 | 321 | 0.150 |
Why?
|
| Recurrence | 1 | 2022 | 1179 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2020 | 77 | 0.150 |
Why?
|
| Hyperbilirubinemia | 1 | 2018 | 21 | 0.150 |
Why?
|
| Adult | 12 | 2021 | 27494 | 0.140 |
Why?
|
| Risk Factors | 3 | 2020 | 5697 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 45 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2018 | 232 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 147 | 0.130 |
Why?
|
| Prevalence | 2 | 2018 | 1293 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 960 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 170 | 0.130 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.130 |
Why?
|
| Blood Culture | 1 | 2016 | 11 | 0.130 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 35 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2017 | 324 | 0.120 |
Why?
|
| Bone Marrow Examination | 1 | 2015 | 46 | 0.120 |
Why?
|
| Philadelphia Chromosome | 1 | 2015 | 44 | 0.120 |
Why?
|
| Imatinib Mesylate | 1 | 2015 | 127 | 0.120 |
Why?
|
| Bacteremia | 1 | 2016 | 104 | 0.120 |
Why?
|
| Survival Rate | 4 | 2021 | 1924 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 622 | 0.120 |
Why?
|
| Prednisone | 2 | 2017 | 254 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 239 | 0.110 |
Why?
|
| U937 Cells | 2 | 2010 | 32 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 383 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 496 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2016 | 614 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 307 | 0.100 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 17 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2016 | 329 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 976 | 0.100 |
Why?
|
| Pediatrics | 1 | 2017 | 367 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 388 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 59 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 108 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 1013 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 56 | 0.090 |
Why?
|
| Dithiothreitol | 1 | 2010 | 25 | 0.080 |
Why?
|
| Biomarkers | 2 | 2022 | 1846 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2010 | 71 | 0.080 |
Why?
|
| Tretinoin | 1 | 2010 | 131 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 337 | 0.080 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2022 | 111 | 0.080 |
Why?
|
| Quality of Life | 1 | 2017 | 1742 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2010 | 215 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 174 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2010 | 698 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 868 | 0.070 |
Why?
|
| Autophagy | 1 | 2010 | 169 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2010 | 347 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 560 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2010 | 310 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 379 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1904 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 365 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 786 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 873 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2010 | 1142 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 505 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2021 | 151 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 1094 | 0.070 |
Why?
|
| Incidence | 2 | 2024 | 1654 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3768 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1764 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2667 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 1392 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 865 | 0.050 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 4466 | 0.050 |
Why?
|
| Seizures | 1 | 2024 | 313 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2074 | 0.050 |
Why?
|
| Base Sequence | 2 | 2016 | 2317 | 0.050 |
Why?
|
| United States | 3 | 2021 | 7338 | 0.050 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 28 | 0.050 |
Why?
|
| Sepsis | 1 | 2024 | 350 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 855 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 291 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 800 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2018 | 93 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1509 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 1804 | 0.040 |
Why?
|
| Vinblastine | 1 | 2017 | 100 | 0.040 |
Why?
|
| Vincristine | 1 | 2017 | 109 | 0.040 |
Why?
|
| Bleomycin | 1 | 2017 | 103 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2017 | 101 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 304 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 159 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2017 | 296 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1503 | 0.030 |
Why?
|
| Oncologists | 1 | 2016 | 38 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1119 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1731 | 0.030 |
Why?
|
| Marital Status | 1 | 2016 | 43 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 258 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 707 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 196 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 246 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 351 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2972 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 132 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 324 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 899 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1226 | 0.030 |
Why?
|
| Genes, myc | 1 | 2012 | 42 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 50 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 83 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2034 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 77 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 526 | 0.020 |
Why?
|
| World Health Organization | 1 | 2012 | 113 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 221 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5426 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 264 | 0.020 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2010 | 12 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1773 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1916 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 200 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 203 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 185 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 2085 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1239 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 19915 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 12103 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 27974 | 0.010 |
Why?
|